Clinical Trials
3 trialsNCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT00129558 2013-12-04
A Study to Evaluate PT-523 in Patients With Refractory Leukemia
Spectrum Pharmaceuticals, Inc
Phase 1/2 Withdrawn
NCT00044733 2006-05-18
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed